Long‐term efficacy and safety of a permeation‐enhanced testosterone transdermal system in hypogonadal men
The DOI matches its Crossref record.
Abstract
OBJECTIVE: An important aim in treating male hypogonadism is restoration of physiological concentrations of testosterone and its metabolites. We have assessed hormone levels, pharmacokinetics and clinical response, including safety, of a permeation‐enhanced testosterone transdermal system (TTD) in the treatment of hypogonadal men for a 12‐month period. DESIGN: Open‐label, multicentre study with four consecutive periods: Period I (3 weeks)—evaluation of patients' current androgen therapy, which consisted primarily of testosterone enanthate injections (mean dose 229 mg; mean interval 26d); Period II (8 weeks)—androgen washout; Period III (3–4 weeks)—single‐dose pharmacokinetic studies of TTD systems; Period IV (12 months)—efficacy, safety, and steady‐state pharmacokinetic evaluation of TTD systems (5 mg/day nominal delivery rate of testosterone). Results from Periods I, II, and IV were compared. PATIENTS: Thirty‐seven hypogonadal men 21–65 years old enrolled; 34 entered Periods III and IV; 29 (9 primary, 20 secondary hypogonadism) completed the study. Four patients withdrew because of adverse events (Period II, one; Period IV, three). MEASUREMENTS: Morning serum levels of total testosterone (T), bioavailable testosterone (BT), dihydrotestosterone (DHT), and oestradiol (E 2) levels. Circadian pattern of T profiles and 24‐hour time‐average T level. LH levels in patients with primary hypogonadism. Reduction of hypogonadal symptoms. Safety assessments including skin tolerability, prostate parameters, lipid profile, and systemic parameters. RESULTS: Twelve months of TTD therapy normalized morning serum T levels in 93% of patients, and produced greater than 80% normalization of BT, DHT and E 2 levels. The TTD system mimicked the circadian variation in T levels seen in healthy young men and normalized 24‐hour time‐average T levels in 86% of patients. Luteinizing hormone was suppressed in 8 of 9 men with primary hypogonadism, and normalized in 5 of these. Subjective symptoms of hypogonadism, including decreased libido and fatigue, showed improvement after 2–4 weeks of TTD treatment in most patients. The majority of adverse events were local skin reactions, and 3 patients (9%) discontinued the study for this reason. Prostate assessments showed a lower prostate‐specific antigen level during TTD therapy compared to IM injections (0.66 vs 1.00 μg/l P < 0.001), while prostate size did not differ significantly between the two treatment regimens. CONCLUSIONS: The permeation‐enhanced testosterone transdermal system produces physiological levels and circadian patterns of testosterone, and its metabolites, in hypogonadal men. Although transient erythema and itching is commonly reported, the TTD is generally well tolerated by most patients. This system offers a new treatment option for testosterone replacement therapy that results in physiological serum levels of sex hormones in hypogonadal men.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Wang, C., Cunningham, G., Dobs, A., Iranmanesh, A., Matsumoto, A. M., Snyder, P. J., Weber, T., Berman, N., Hull, L., & Swerdloff, R. S. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032006 · Cited by 656
“The number of subjects with high hemoglobin or hematocrit that required discontinuation was similar to other reports (23, 34, 35).”
ResultSelf-citationEnglish, K. M., Steeds, R. P., Jones, T. H., Diver, M. J., & Channer, K. S. (2000) · Circulation · doi:10.1161/01.cir.102.16.1906 · Cited by 582
Malkin, C. J., Pugh, P. J., West, J. N., van Beek, E. J. R., Jones, T. H., & Channer, K. S. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehi443 · Cited by 413
Steidle, C., Schwartz, S., Jacoby, K., Sebree, T., Smith, T., & Bachand, R. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021058 · Cited by 411
Dobs, A. S. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.10.3469 · Cited by 381
“For TTD, the results were consistent with earlier studies (8, 16) that showed that the nightly application of two TTD systems resulted in morning peaks and evening nadirs similar to the circadian profiles observed in healthy young men (3).”
ResultSelf-citation
Metadata
- Authors
- Arver, S., Dobs, A. S., Meikle, A. W., Caramelli, K. E., Rajaram, L., Sanders, S. W., & Mazer, N. A.
- Venue
- Clinical Endocrinology
- Publisher
- Wiley
- Published
- 1997-12
- Volume
- 47
- Issue
- 6
- Pages
- 727-737
- ISSN
- 0300-0664 (ISSN-L)
- 1365-2265
- OpenAlex
- W1969032321
- Cited by
- 128
- References
- 0
- FWCI
- 4.64
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long‐term efficacy and safety of a permeation‐enhanced testosterone transdermal system in hypogonadal men. https://app.cochat.ai/papers/10.1046/j.1365-2265.1997.3071113.x
- The paper
- Arver, S., Dobs, A. S., Meikle, A. W., Caramelli, K. E., Rajaram, L., Sanders, S. W., & Mazer, N. A. (1997). Long‐term efficacy and safety of a permeation‐enhanced testosterone transdermal system in hypogonadal men. Clinical Endocrinology. https://doi.org/10.1046/j.1365-2265.1997.3071113.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.